Certolizumab pegol治疗斑块状银屑病3年长期安全性:三项III期随机安慰剂对照研究汇总分析
汇总CIMPASI-1、CIMPASI-2和CIMPACT三项III期随机安慰剂对照研究,评估Certolizumab pegol(CZP)治疗中重度斑块状银屑病长达144周的安全性。
要点
- 活动性结核1例,恶性肿瘤16例(14例患者),死亡7例(2例与治疗相关)。
核心结论
- 与既往报告数据相比未发现新的安全性信号,风险未随CZP暴露时间延长或剂量增加而升高。
研究设计与样本
- 汇总三项III期随机安慰剂对照研究(CIMPASI-1、CIMPASI-2、CIMPACT)数据。
- 纳入中重度斑块状银屑病病程≥6个月、随机接受CZP 200mg每2周或400mg每2周、至少接受一剂且暴露长达144周的患者。
临床怎么用
- 长期使用CZP治疗中重度斑块状银屑病时,严重感染、结核、恶性肿瘤和死亡风险与既往已知安全性特征一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Certolizumab pegol (CZP) is an Fc-free, PEGylated anti-tumour necrosis factor biologic. OBJECTIVES: To report 3-year safety data from three phase III trials of CZP in adults with plaque psoriasis. METHODS: Data were pooled from CIMPASI-1 (NCT02326298), CIMPASI-2 (NCT02326272) and CIMPACT (NCT02346240). Included patients had moderate-to-severe plaque psoriasis of ≥ 6 months' duration; had been randomized to CZP 200 mg every 2 weeks (Q2W) (400 mg at weeks 0, 2 and 4) or CZP 400 mg Q2W; and had received at least one dose of CZP with up to 144 weeks of exposure. Treatment-emergent adverse events (TEAEs) were classified using MedDRA v18·1. Reported incidence rates (IRs) are incidence of new cases per 100 patient-years (PY). RESULTS: Over 144 weeks, 995 patients received at least one dose of CZP (exposure: 2231·3 PY); 731 and 728 received at least one dose of CZP 200 mg Q2W (1211·4 PY) and/or 400 mg Q2W (1019·9 PY), respectively. The IR [95% confidence interval (CI)] of TEAEs was 144·9 (135·3-155·0) for all patients, 134·1 (123·2-145·7) for CZP 200 mg Q2W and 158·3 (145·5-171·9) for CZP 400 mg Q2W. The IR (95% CI) of serious TEAEs for all patients was 7·5 (6·4-8·8); the IRs were 6·7 (5·2-8·3) and 8·7 (6·9-10·8) for CZP 200 mg and 400 mg Q2W, respectively. Overall, 3·2% of patients reported serious infections (2·2% within each of the CZP 200 and 400 mg Q2W groups). Overall, there was one case of active tuberculosis, 16 malignancies in 14 patients and seven deaths (two considered treatment-related). The cumulative IR of TEAEs did not increase over time. CONCLUSIONS: No new safety signals were identified compared with previously reported data. Risk did not increase with longer or higher CZP exposure.
引用
- Blauvelt A, Paul C, van de Kerkhof P, et al. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies. Br J Dermatol. 2020. PMID: 32531798. doi:10.1111/bjd.19314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。